ストックスクリーナーアプリを入手
477.60
3.06%
14.18
アフターアワーズ：
477.60
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal Sets Date to Reveal 2025 Results as Investors Watch Closely - MyChesCo
Aug Update: Is Madrigal Pharmaceuticals Inc stock good for income investorsRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
21 new Madrigal hires receive 5,861 stock units vesting over 4 years - stocktitan.net
Commit To Buy Madrigal Pharmaceuticals At $350, Earn 14.6% Annualized Using Options - Nasdaq
Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth - Investing.com Canada
Madrigal Pharmaceuticals to report financial results on February 19 - Traders Union
18,291 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by WCM Investment Management LLC - MarketBeat
How (MDGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Novo Set To Make MASH Move On Madrigal In EU With Kayshild - Citeline News & Insights
Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Quiver Quantitative
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and - GlobeNewswire
Madrigal Pharmaceuticals (MDGL) Price Target Increased by 10.39% to 562.78 - MSN
Pharma News: How does INNV perform in inflationary periods2025 Trading Recap & Weekly Stock Performance Updates - baoquankhu1.vn
Valuation Update: Will Madrigal Pharmaceuticals Inc outperform during market rallies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Breakouts Watch: What are analysts price targets for Madrigal Pharmaceuticals IncCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Bull Bear: Is Madrigal Pharmaceuticals Inc stock a value trapIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
New York State Common Retirement Fund Grows Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche - TipRanks
Madrigal Pharmaceuticals Signs Amendment to Research and Commercialization Agreement With Roche - TradingView
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Madrigal Weighs Pfizer MASH License And Insider Selling In Growth Plan - Sahm
Is Madrigal Pharmaceuticals Inc. stock a value trapTrade Entry Report & Technical Entry and Exit Alerts - mfd.ru
Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Barclays - MarketBeat
J. Safra Sarasin Holding AG Sells 4,426 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Rezdiffra Sales Milestone and Pfizer DGAT-2 Deal Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL) - Sahm
Nonalcoholic Steatohepatitis Market to Evolve Rapidly Over the Next Decade, DelveInsight Observes | Madrigal Pharmaceuticals, Novo Nordisk, 89bio - Barchart.com
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates - MyChesCo
Can Madrigal Pharmaceuticals Inc. stock double in the next yearQuarterly Trade Summary & AI Driven Stock Movement Reports - mfd.ru
MDGL: Barclays Initiates Coverage with Overweight Rating | MDGL Stock News - GuruFocus
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet - mychesco.com
Is Madrigal Pharmaceuticals (MDGL) Still Attractively Priced After Recent Share Price Pullback? - Yahoo Finance
Madrigal Pharmaceuticals Lobbying And Insider Sales Put Valuation In Focus - Sahm
EFG Asset Management North America Corp. Acquires New Shares in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Taub, Madrigal Pharmaceuticals director, sells $318k in shares By Investing.com - Investing.com Canada
Carole Huntsman Sells 910 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 1,577 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Rebecca Taub Sells 647 Shares - MarketBeat
Huntsman, chief commercial officer, sells $449k in Madrigal (MDGL) By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan - MSN
Fundamentals Check: Will AMZE outperform during market ralliesQuarterly Trade Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Volume Recap: Will Madrigal Pharmaceuticals Inc benefit from seasonalityJuly 2025 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Trading Systems Reacting to (MDGL) Volatility - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 5.1%Here's Why - MarketBeat
Relative Strength Alert For Madrigal Pharmaceuticals - Nasdaq
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations - Sahm
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aug Decliners: Will MAYAR outperform small cap indexesJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Lobbying Update: $280,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Emerald Advisers LLC Sells 2,371 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals announces grant of inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grant Of Inducement Award Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taub Rebecca, director at Madrigal, sells $1.09m in MDGL stock - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Sells $344,173.12 in Stock - MarketBeat
Kelley, Madrigal Pharmaceuticals general counsel, sells $344,172 in MDGL By Investing.com - Investing.com Canada
MDGL: Analyst Jonathan Wolleben Raises Price Target to $745 | MD - GuruFocus
Citizens Jmp Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $745.00 - MarketBeat
10 Analysts Have This To Say About Madrigal Pharmaceuticals - Benzinga
0.23%
1.25%
大文字化:
|
ボリューム (24 時間):